ankyrin repeat and SOCS box containing 12Genealiases: []
Q-omics provides the consensus-scored ASB12 profile across patient tissues and cancer cell-line models. ASB12 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ASB12 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ASB12 RNA expression shows 14,497 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LGG, HNSC, and KIRP as cancer lineages where ASB12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASB12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASB12 survival associations across molecular data types. ASB12 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASB12 RNA expression–survival associations across cancer types. High ASB12 expression shows favorable associations in LGG, STAD, SARC, PAAD, UCS and COAD. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ASB12 RNA expression.
This table summarizes ASB12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ASB12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASB12 shows lower tumor expression in HNSC, BLCA, BRCA, LUSC, KICH and LUAD. The HNSC box plot shows higher ASB12 RNA expression in normal versus tumor tissue (log2 FC = −1.326, t-test p < 0.001).
This table shows molecular features associated with ASB12 in patient tissues and cancer cell lines. In patient samples, ASB12 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ASB12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
